Citius Oncology Expands LYMPHIR EU Distribution With Exclusive Uniphar Partnership

Citius Oncology (NASDAQ: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals (NASDAQ: CTXR), has signed an exclusive European Union distribution agreement for its oncology immunotherapy LYMPHIR™ with global healthcare services company Uniphar. The move accelerates LYMPHIR’s international rollout and strengthens the company’s commercial growth strategy.

Citius Oncology Accelerates European Market Access

Under the agreement, Uniphar will actively manage EU distribution, logistics, and market access support for LYMPHIR. As a result, Citius Oncology can move faster across key European markets and improve product availability for eligible patients. Instead of building regional infrastructure alone, the company now leverages Uniphar’s established specialty pharma network.

Moreover, this partnership follows earlier international expansion steps and shows a consistent push to scale LYMPHIR beyond the U.S. market. With each added distributor, Citius Oncology increases its commercial reach and shortens time to market.

LYMPHIR Targets a High-Need CTCL Treatment Segment

LYMPHIR treats relapsed or refractory cutaneous T-cell lymphoma (CTCL), a rare and difficult-to-treat cancer. Because later-line CTCL patients often have limited therapy options, demand for new immunotherapy approaches remains strong. Therefore, broader EU distribution could meaningfully expand the addressable patient population.

In addition, the European oncology drug market ranks among the largest globally. That scale gives LYMPHIR a larger commercial runway as reimbursement and physician adoption develop country by country.

Investor Impact: Growth, Reach, and Execution

From an investor perspective, the EU distribution deal supports several SEO-relevant growth themes: international oncology expansion, LYMPHIR commercialization progress, and CTCL treatment market growth.

Specifically:

• First, geographic expansion increases potential LYMPHIR revenue channels.
• Next, commercial leverage improves because Uniphar already operates a scaled distribution platform.
• Additionally, execution risk drops when experienced partners handle regional logistics and access.
• Lastly, the platform’s credibility rises as more established distributors align with the product.

Going forward, investors should track EU launch timing, reimbursement decisions, and early international sales trends. Together, these milestones will show how effectively Citius Oncology converts distribution partnerships into measurable oncology revenue growth.